Regulatory Replimune gets early August decision date for twice-rejected melanoma drug BioSpaceReplimune's resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug's first two rejections.OncologyRead full story pharminent June 26, 2026 (Last updated: June 26, 2026) BioSpace Replimune’s resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug’s first two rejections. Oncology Read full story Post navigation Previous: Moderna looks out to R&D ‘horizons’ as 2028 break-even goal loomsNext: Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026